SHARE

Mind Solutions Inc (OTCMKTS:VOIS) is pleased to announce that it has signed a marketing agreement for the product launch of Neurosync — the smallest brain-computer interface device. As per the reports, it has signed a marketing agreement with a Top 10 Inc. 500 Marketing company, which will take care of all the online sales activities of Neurosync.

Insights On The Matter:

Online sales of this top-notch product will begin on July 15, 2015 for the public. Top 10 Inc. 500 Marketing company is one of the most sought after marketing agencies in the country. It will come up with a proactive marketing campaign to enhance the online sales of Neurosync. It is known for world-class tracking, statistics and analytics; hence, the end-result is expected to be at par or more than Mind Solutions’ expectations.

Mind Solutions Inc. doesn’t want to leave any stone unturned; hence, it has made available this product on multiple platforms. Apart from direct online sales through Top 10 Inc. 500 Marketing company, users can also find it at Amazon. The company had made clear its intentions previously; therefore, the announcement concerning Amazon was not a surprise for all of its shareholders.

The Road Ahead:

As of now, Mind Solutions is in the process to prepare a video advertisement for Neurosync, which can be used on digital media i.e. TV and various social media platforms like Facebook and other sites. The preparation is going on at a swift speed, and a further update will be shared with all the shareholders as the time progresses.

The senior management team of the company is excited to share this information and hopes that the product will live up to customers’ expectations. According to Kerry Driscoll, Chief Executive Officer, Mind Solutions, it’s great to see everything is on track. The company is expecting the delivery of Neurosync this month.

Mind Solutions Inc (OTCMKTS:VOIS) will keep updating about the growth of Neurosync from time to time in the future.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of journaltranscript.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:

https://www.journaltranscript.com/disclaimer

LEAVE A REPLY